Home
Products
Ferruginol
| Product Name | Ferruginol |
| Price: | Inquiry |
| Catalog No.: | CN08624 |
| CAS No.: | 514-62-5 |
| Molecular Formula: | C20H30O |
| Molecular Weight: | 286.5 g/mol |
| Purity: | >=98% |
| Type of Compound: | Diterpenoids |
| Physical Desc.: | Powder |
| Source: | The herbs of Salvia yunnanensis |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| SMILES: |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Ferruginol ((+)-Ferruginol), a natural diterpenoid, is an inhibitor of the activation of Epstein-Barr virus early antigen (EBV-EA). Ferruginol inhibits the growth of thyroid cancer cells through the induction of mitochondrial Apoptosis. Ferruginol has antitumor, cardioprotective, antioxidant, gastroprotective, and neuroprotective activities[1][2][3]. |
| In Vitro | Ferruginol（0-160 μM；24 小时）对甲状腺癌细胞具有有效的抗增殖作用，对 MDA-T32 细胞系的 IC50 为 12 μM。Ferruginol 对正常细胞的毒性作用不太明显[1]。 Ferruginol（0-24 μM；24 小时）诱导 MDA-T32 细胞的凋亡性细胞死亡。Ferruginol 剂量依赖性地增加 Bax 表达并降低 Bcl-2 表达[1]。 Ferruginol（0-24 μM；24 小时）抑制 MDA-T32 细胞的 MAPK 和 PI3K/AKT 信号通路[1]。 Ferruginol（0-24 μM；24 小时）还会引起 ROS 介导的 MDA-T32 细胞基质金属蛋白酶改变[1]。 Cell Viability Assay[1] Cell Line: MDA-T32 cells Concentration: 0-160 μM Incubation Time: 24 hours Result: Exerted potent antiproliferative action against thyroid cancer cells. Apoptosis Analysis[1] Cell Line: MDA-T32 cells Concentration: 0 μM, 6 μM, 12 μM, and 24 μM Incubation Time: 24 hours Result: Induced apoptotic cell death of MDA-T32 cells Western Blot Analysis[1] Cell Line: MDA-T32 cells Concentration: 0 μM, 6 μM, 12 μM, and 24 μM Incubation Time: 24 hours Result: Blocked the MAPK and PI3K/AKT signaling pathway. |
| In Vivo | Ferruginol（20 mg/kg；口服；每天；持续 4 周）发挥心脏保护作用，表现为增强的心脏功能和减少的结构损伤和细胞凋亡。转录组和其他结果表明，Ferruginol 通过增加 PGC-1α 的表达并同时促进 SIRT1 增强脱乙酰酶 SIRT1 去乙酰化和激活 PGC-1α 的表达，促进 PGC-1α 介导的线粒体生物发生和脂肪酸氧化 (MB 和 FAO)[3]。 Animal Model: Male C57BL/6 mice (20 g, 8-10 weeks old) with Doxorubicin (DOX)-induced cardiotoxicity (DIC)[3]. Dosage: 20 mg/kg Administration: Administered intragastrically; daily; for 4 weeks Result: Relieved Doxorubicin-induced cardiac structural and functional lesion. |
| Density | 1.0±0.1 g/cm3 |
| Boiling Point | 388.1±31.0 °C at 760 mmHg |
| Flash Point | 175.1±14.5 °C |
| Exact Mass | 286.229675 |
| PSA | 20.23000 |
| LogP | 7.57 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |